Clinical Oncology: Case Reports

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Aneke Gansewig Author

Subjects of specialization
cancer, cancer oncology, Carcinogenesis

Affiliation
Department of Pharmacy, University Hospital Lubeck, Germany

Biography

Dr. Aneke Gansewig is working as scientist and professor at Department of Pharmacy, University Hospital Lubeck, Germany. The author has specalization in cancer, cancer oncology, chemotherapy, Carcinogenesis, Chemotherapy


Publications

Case Report Subscription

Autoimmune Toxicity Following Nivolumab and Ipilimumab Therapy For Hepatocellular Carcinoma-An Interdisciplinary Challenge

Author(s):

Matthias Mezger, Cara Harms, Karolin Schmoll, Aneke Gansewig, Ingo Eitel, Nikolas von Bubnoff and Tobias Graf

Abstract

Over the last years, several new drugs have been launched for the treatment of cancer. Immune checkpoint blockade suppresses intrinsic down-regulators of immunity, such as cytotoxic T-lymphocyte Antigen 4 (CTLA-4) and Programmed Cell Death 1 (PD-1) or its ligand, Programmed Cell Death Ligand 1 (PD-L1). Immune checkpoint blockade enhances patient´s immune system and increased survival rates for different cancer subtypes. However, immune checkpoint blockade can lead to autoimmunity with a multitude of side effects that involve the heart, gastrointestinal tract, endocrine glands, skin, CNS and liver. We here present the case of a patient who was admitted to the emergency department with stroke- like symptoms. Whilst monitoring on stroke- unit was o... view moreĀ»

Abstract HTML PDF



Google Scholars / Researchers Sites

GET THE APP